Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mai 2016 16h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes

New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator...
15 mars 2016 06h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update

BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar...
01 mars 2016 08h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update

BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal...
09 févr. 2016 07h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)

UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global sales of...
05 févr. 2016 16h01 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12

BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
03 févr. 2016 09h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference

BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
16 nov. 2015 06h05 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar)

Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity...
16 nov. 2015 06h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update

BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
11 nov. 2015 16h05 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Reschedules Its Third Quarter 2015 Financial Results Conference Call and Webcast

BOSTON, Nov. 11, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
10 nov. 2015 08h00 HE | Source: EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer

BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...

Page suivante